Table 5.

Main adverse cutaneous side effects related to the use of drugs targeting specific molecular pathways.

Molecular target pathway	Cutaneous side effect
EGFR/HER inhibitor	Papulopustular eruption Xerosis/Pruritus Hair/nail changes
BRAF inhibitor	Keratic lesions Photosensitivity Alopecia Palmoplantar hyperkeratosis Erythema nodosum
MEK inhibitor	Papulopustular/acneiform eruption Maculopapular/exfoliative rash Foliculitis Erysipelas
MTOR inhibitor	Papular/acneiform eruption Onycholysis Acne vulgaris Pruritus/xeroderma
TK inhibitor	Periorbital and lower limb edema Pigmentary changes Hand-foot reaction Maculopapular reaction
Anti-VEGF	Hand-foot syndrome Xerosis Exanthema Delayed wound healing
Immune checkpoint inhibitor	Maculopapular rash Desquamation Psoriasiform reaction Toxic epidermal necrolysis Vitiligoid reaction

EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; HER, human epidermal growth factor; mTOR, mammalian target of rapamycin; MAPK, mitogen-activated protein kinase; MEK, MAPK/ERK kinase; TK inhibitor, tyrosine-kinase inhibitor; VEGF, vascular endothelial growth factor.